nach oben

Acta Diabetologica

Erschienen in:

01.09.2008 | Original Article

Diabetes and impaired glucose tolerance prevalences in Turkish patients with impaired fasting glucose

verfasst von: Pelin Tutuncuoğlu, Fulden Saraç, Füsun Saygılı, A. Gökhan Ozgen, Candeğer Yılmaz, Mehmet Tüzün

Erschienen in: Acta Diabetologica | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Impaired fasting glucose (IFG) like impaired glucose tolerance (IGT) has increased risk of progressing to diabetes mellitus (DM). The aim of the study was to evaluate prevalance of IGT and type 2 DM with oral glucose tolerance test (OGTT) in Turkish patients who had fasting glucose of 110 and 125 mg/dl. Hundred and forty-eight (67.3%) women and 72 (32.7%) men (30–65 years old with mean age of 51.3 ± 8.7 year) who had fasting glucose range 110–125 mg/dl were evaluated with OGTT. Seventy-two patients had IGT (32.8%), 74 (33.6%) patients had type 2 diabetes and 74 (33.6%) patients had normal glucose tolerance (NGT). Mean fasting glucose and insulin levels were higher in the IGT group than in the NGT group. Mean level of total cholesterol was higher in DM than that in NGT and IGT groups. Mean triglyceride (TG) (P = 0.476), high-density lipoprotein (HDL) (P = 0.594), low-density lipoprotein (LDL) (P = 0.612), Apoproteine A (P = 0.876), Apoproteine B (P = 0.518), uric acid (P = 0.948) and ferritin (P = 0.314) were found higher in diabetic patients. Lipoproteine a (P = 0.083), fibrinogen (P = 0.175) and hsCRP (P = 0.621) levels were higher in IGT. Mean HOMA S% levels of NGT, IGT and DM were found to be 65.0 ± 13.0%, 60.9 ± 16.0% and 50.1 ± 11.1%, respectively. HOMA B% levels were measured to be 80.4 ± 29.1% in NGT, 85.3 ± 14.59% in IGT and 60.1 ± 10.1% in DM. Significant difference was found between IFG and DM (P = 0.043) groups. The prevalences of diabetes and IGT were found to be 33.63 and 32.7% in IFG, respectively.

Susman JL, Helseth LD (1997) Reducing the complications of type II diabetes: a patient-centered approach. Am Fam Physician 56:471–480PubMed

Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20:1183–1197

Engelgau MM, Thompson TJ, Herman WH, Boyle JP, Aubert RE, Kenny SJ, Badran A, Sous ES, Ali MA (1997) Comparison of fasting 2-hour glucose and HbA levels for diagnosing diabetes: diagnostic criteria and performance revisited. Diabetes Care 20:785–791PubMedCrossRef

Balkan B, Bertrais S, Ducimetiere P, Eschwege E (1999) Is there a glycaemic threshold for mortality risk? Diabetes Care 22:696–699CrossRef

National Diabetes Data Group (1979) Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039–1057

Harris MI (1996) Impaired glucose tolerance–prevalence and conversion to NIDDM. Diabet Med 13(Suppl 2):9–11

Harris MI, Hadden WC, Knowler WC, Benneth PH (1987) Prevelance of diabetes and impaired glucose tolerance and plazma glucose levels in US population aged 20–74. Diabetes 36:523–534PubMedCrossRef

Hertzel C, Gerstein MD (2001) Fasting versus postload glucose levels: why the controversy? Diabetes Care 24:1855–1857CrossRef

Finch CF, Zimmet PZ, Alberti KGMM (1990) Determinig diabetes prevelance; a rational basis for the use of fasting plazma glucose consentation? Diabet Med 7:603–610PubMedCrossRef

10.

American Diabetes Assosiation (1997) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20:1183–1197

11.

Charles MA, Balkan B (1996) Revision of diagnostic criteria for diabetes [letter]. Lancet 348:1657–1658PubMedCrossRef

12.

Alberti KGMM, Zimmet PZ, for the WHO Consultation Group (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part1: diagnosis classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 15:539–553

13.

Harris MI, Flegal KM, Cowie C et al (1998) Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care 21:1518–1524

14.

De Vegt F, Dekker JM, Stehouwer CDA, Nijpels G, Bouter LM, Heine RJ (1998) The 1997 American Diabetes Assosiation criteria versus the 1985 World Health Organization criteria for the diagnosis of abnormal glucose tolerance. Diabetes Care 21:1686–1690PubMedCrossRef

15.

Barrett-Connor E, Ferrara A (1998) Isolated postchallenge hyperglycemia and risk of fatal cardiovasculer diseases older women and men. Diabetes Care 21:1236–1239PubMedCrossRef

16.

Shaw JE, Hodge AM, de Courten M, Chitson P, Zimmet PZ (1999) İsolated postchallenge hyperglycemia confirmed as a risk factor of mortality. Diabetologia 42:1050–1054PubMedCrossRef

17.

Barzilay JI, Spiekerman CF, Wahl PW et al. (1999) Cardiovasculer diseases in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria. Lancet 354:1622–1655

18.

DECODE Study Group, for the European Diabetes Epidemiology Group (1999) Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic crireria. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet 354:617–621

19.

Alberti KGMM (1996) The clinical implications of impaired glucose tolerance. Diabet Med 13:1927–1937CrossRef

20.

Unwin N, Shaw J, Zimmet P, Alberti KG (2002) Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 19:1708–1723

21.

UK Prospective Diabetes Study Group (1998) Tight blood preasure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 317:1703–1713

22.

American Diabetes Association (2005) Diagnosis and classification of diabetes mellitus. Diabetes Care 28:37–42CrossRef

23.

Oxford Diabetes web site Oxford Centre for Diabetes, Endocrinology and Metabolism—website. The Diabetes Trials Unit. http://www.dtu.ox.ac.uk/

24.

Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22(9):1462–1470PubMedCrossRef

25.

Stumvoll M, Van Haeften T, Fritsche A, Gerich J (2001) Oral glucose tolerance test indexes for insulin sensitivity and secretion based on various availabilities of sampling times. Diabetes Care 24(4):796–797PubMedCrossRef

26.

Dunstan DW, Zimmet PZ, Welborn TA, De Courten MP, Cameron AJ, Sicree RA, Dwyer T, Colagiuri S, Jolley D, Knuiman M, Atkins R, Shaw JE (2002) The rising prevalence of diabetes and impaired glucose tolerance: the Australian diabetes, obesity and lifestyle study. Diabetes Care 25:1829–1834CrossRef

27.

Jensen CC, Cnop M, Hull RL, Fujimato WY, Kahn SE, for the American Diabetes Assosiation GENNİD Study Group (2002) Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S. Diabetes 5:2170–2178

28.

Perry IJ, Wannamethee SG, Walker MK, Thomson AG, Whincup PH, Shaper AG (1995) Prospective study of risk factors for development of non-insulin dependent diabetes in middle aged British men. BMJ 310:560–564PubMed

29.

Gu D, Reynolds K, Duan X, Xin X, Chen J, Wu X, Mo J, Whelton PK, HeJ (2003) Prevalence of diabetes and impaired fasting glucose in the Chinese adult population: international collaborative study of cardiovascular disease in Asia (InterASIA). Diabetologia 46:1190–1198PubMedCrossRef

30.

Weyer C, Bogardus C, Pratley RE (1999) Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 48:2197–2203PubMedCrossRef

31.

Abdul-Ghani MA, Tripathy D, DeFronzo RA (2006) Contributions of {beta}-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 29:1130–1139PubMedCrossRef

32.

Davies MJ, Raymond NT, Day JL, Hales C, Burden AC (2000) Impaired glucose tolerance and fasting hyperglycaemia have different characteristics. Diabet Med 17:433–440PubMedCrossRef

33.

Shaw JE, Zimmet PZ, de Courten M, Dowse GK, Chitson P, Gareeboo H, Hemraj F, Fareed D, Tuomilehto J, Alberti KG (1999) Impaired fasting glucose or impaired glucose tolerance: what best predicts future diabetes in Mauritius? Diabetes Care 22:399–402PubMedCrossRef

34.

Gabir MM, Hanson RL, Dabelea D, Imperatore G, Roumain J, Bennett PH, Knowler WC (2000) The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 23:1108–1112PubMedCrossRef

35.

The DECODE Study Group, for the European Diabetes Epidemiology Study Group (1998) Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. BMJ 317:371–375

36.

Davidson MB, Peters AL, Schriger DL (1995) An alternative approach to the diagnosis of diabetes with a review of the literature. Diabetes Care 8:1065–1071

37.

Abdul-Ghani M, Williamsn K, DeFronzo R, Stern M (2006) Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose. Diabetes Care 29:1613–1618PubMedCrossRef

38.

Meigs JB, Muller DC, Nathan DM, Blake DR, Andres R (2003) The natural history of progression from normal glucose tolerace to type 2 diabetes in the Baltimore longitudinal study of aging. Diabetes 52:1475–1484PubMedCrossRef

39.

Williams JW, Zimmet PZ, Shaw JE, de Courten MP, Cameron AJ, Chitson P, Tuomilehto J, Alberti KG (2003) Gender differences in the prevalence of impaired fasting glycaemia and impaired glucose tolerance in Mauritius. Does sex matter? Diabet Med 20:915–20PubMedCrossRef

40.

The DECODE Study Group (2002) Age, body mass index and glucose tolerance in 11 European population-based surveys. Diabet Med 19:558–565CrossRef

41.

Dunstan DW, Zimmet PZ, Welborn TA, De Courten MP, Cameron AJ, Sicree RA (2002) The rising prevalence of diabetes and impaired glucose tolerance: the Australian diabetes, obesity and lifestyle study. Diabetes Care 25:829–834PubMedCrossRef

42.

Zargar AH, Khan AK, Masoodi SR, Laway BA, Wani AI, Bashir MI et al (2000) Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in the Kashmir Valley of the Indian subcontinent. Diabetes Res Clin Pract 47:135–146PubMedCrossRef

43.

Omar MA, Seedat MA, Dyer RB, Motala AA, Knight LT, Becker PJ (1994) South African Indians show a high prevalence of NIDDM and bimodality in plasma glucose distribution patterns. Diabetes Care 17:70–73PubMedCrossRef

44.

Tripathy D, Carlsson M, Almgren P, Isomaa B, Taskinen MR, Tuomi T, Groop LC (2000) Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia study. Diabetes 49:975–980PubMedCrossRef

45.

Davies MJ, Raymond NT, Day JL, Hales CN, Burden AC (2000) Impaired glucose tolerance and fasting hyperglycaemia have different characteristics. Diabet Med 17:433–440PubMedCrossRef

46.

Güney E, Özgen G, Kısakol G (2002) Impact of new diagnostic criteria on the frequency of diabetes mellitus and prediabetic conditions. Int J Diabetes Metab 10:22–28

Titel: Diabetes and impaired glucose tolerance prevalences in Turkish patients with impaired fasting glucose
verfasst von: Pelin Tutuncuoğlu
Fulden Saraç
Füsun Saygılı
A. Gökhan Ozgen
Candeğer Yılmaz
Mehmet Tüzün
Publikationsdatum: 01.09.2008
Verlag: Springer Milan
Erschienen in: Acta Diabetologica / Ausgabe 3/2008
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-008-0034-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2008

Effect of early insulin therapy on nuclear factor κB and cytokine gene expressions in the liver and skeletal muscle of high-fat diet, streptozotocin-treated diabetic rats

Exercise just before glucose ingestion does not deteriorate glucose tolerance in well controlled patients with type 2 diabetes mellitus who exercise regularly

Adipocytes in subjects with impaired fasting glucose and impaired glucose tolerance are resistant to the anti-lipolytic effect of insulin

Neutrophil surface expression of CD11b and CD62L in diabetic microangiopathy

Effects of thiamine and benfotiamine on intracellular glucose metabolism and relevance in the prevention of diabetic complications